生物学的抗リウマチ薬に抵抗性の活動性関節リウマチ患者におけるウパダシチニブの安全性と有効性 (SELECT-BEYOND): 二重盲検, 無作為化対照フェーズ 3 治験
Lancet 2018;391:2513–24
Upadacitinib (UPA) extended release formulation was effective in treating patients with moderate-to-severe RA with an inadequate response to bDMARDs.Phase 2 study data has shown that UPA is an efficacious and safe treatment for active RA.1,2 SELECT-BEYOND was a double-blind, long-term extension, Phase 3 study to assess the efficacy of UPA in patients with RA who were bDMARD-IR. The first 12-weeks of SELECT-BEYOND were placebo-controlled, with a double-blind period followed by an ongoing double-b...